T细胞亚群在肺纤维化过程中的研究进展

doi:10.20047/j.issn1673-7210.2023.27.08

摘要
图/表
参考文献(41)
相关文章 (15)

全文: PDF (518 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要肺纤维化是一种以肺组织结构改变为主要特征的慢性间质性疾病，特发性肺纤维化是其中最为严重的一种。特发性肺纤维化病因不明，发病机制复杂，以T淋巴细胞为主导的免疫炎症在肺纤维化进程中发挥关键作用。根据其在免疫炎症中的不同途径将T细胞分为不同亚群：Th细胞、Treg细胞、Tc细胞及NKT细胞。不同T淋巴细胞亚群及其介导的细胞因子在肺纤维化中高度表达，通过释放或抑制炎症细胞因子的方式调节肺纤维化中的免疫损伤及炎症反应，进而影响肺组织损伤、胶原蛋白分泌及肌成纤维细胞增生的程度，以此参与肺纤维化的进程。本文围绕T细胞亚群及其诱导的细胞因子在肺纤维化进程中的不同病理反应进行综述，探讨其在肺纤维化进程中的作用机制，可为肺纤维化的临床治疗和基础研究提供更深层次的探索方向。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	千孟丹1　　马宁怡2　　王炎1　　李亚3

关键词 ：特发性肺纤维化, 免疫炎症, T淋巴细胞, 细胞因子

Abstract：Pulmonary fibrosis is a chronic interstitial disease characterized by changes in lung tissue structure, and idiopathic pulmonary fibrosis is the most serious one. The etiology of idiopathic pulmonary fibrosis is unknown and the pathogenesis is complex, with T lymphocyte-dominated immune inflammation playing a key role in the lung fibrosis process. T cells are classified into different subpopulations according to their different pathways in immune inflammation: Th cells, Treg cells, Tc cells, and NKT cells. Different T lymphocyte subsets and cytokines mediated by them are highly expressed in pulmonary fibrosis, which can regulate immune injury and inflammatory reaction in pulmonary fibrosis by releasing or inhibiting inflammatory cytokines, and then affect the degree of lung tissue injury, collagen secretion and myofibroblast proliferation, so as to participate in the process of pulmonary fibrosis. In this article, the different pathological responses of T cell subsets and their induced cytokines in the process of pulmonary fibrosis are reviewed, and the mechanisms of their action in the process of pulmonary fibrosis is discussed, which could provide a deeper direction for the clinical treatment and basic research of pulmonary fibrosis.

Key words： Idiopathic pulmonary fibrosis Immune inflammation T lymphocyte Cytokines

基金资助:国家自然科学基金面上项目（81673775、82074 403）；
河南省中医药科学研究专项课题（20-21ZY1019）；
河南省特色骨干学科中医学学科建设项目（STG-ZYXKY- 2020014）。

通讯作者: 李亚（1980.5-），男，博士，副主任医师，主要从事中医药防治呼吸系统疾病研究。

作者简介: 千孟丹（1994.12-），女，河南中医药大学第一临床医学院2020级中医内科学专业在读硕士研究生，主要从事中医药防治呼吸系统疾病研究。

引用本文:

千孟丹1　　马宁怡2　　王炎1　　李亚3. T细胞亚群在肺纤维化过程中的研究进展[J]. 中国医药导报, 2023, 20(27): 39-42.
QIAN Mengdan1 MA Ningyi2 WANG Yan1 LI Ya3. Research progress of T cell subsets in the process of pulmonary fibrosis. 中国医药导报, 2023, 20(27): 39-42.

链接本文:

https://www.yiyaodaobao.com.cn/CN/10.20047/j.issn1673-7210.2023.27.08 或 https://www.yiyaodaobao.com.cn/CN/Y2023/V20/I27/39

[1] Piotrowski WJ，Bestry I，Bialas AJ，et al. Guidelines of the polish respiratory society for diagnosis and treatment of idiopathic pulmonary fibrosis [J]. Adv Respir Med，2020，88（1）：41-93.
[2] Kropski JA，Blackwell TS. Progress in understanding and trea- ting idiopathic pulmonary fibrosis [J]. Annu Rev Med，2019， 70：211-224.
[3] Yamazaki R，Nishiyama O，Yoshikawa K，et al. Clinical course and prognosis in survivors of acute exacerbations of idiopathic pulmonary fibrosis [J]. Respir Investig，2021，59（4）：408- 413.
[4] Gulati S，Thannickal VJ. The aging lung and idiopathic pulmonary fibrosis [J]. Am J Med Sci，2019，357（5）：384-389.
[5] Glass DS，Grossfeld D，Renna H A，et al. Idiopathic pulmonary fibrosis：current and future treatment [J]. Clin Respir J，2022， 16（2）：84-96.
[6] 李星，朱振华，吴仲敏，等.PPARγ激活剂对博莱霉素诱导小鼠肺纤维化的改善作用[J].中华全科医学，2021，19（9）：1455-1458.
[7] 蔡欣，李炎玉，苏国媚，等.膜联蛋白A1促进肺成纤维细胞炎症反应及胶原合成的研究[J].中华全科医学，2021， 19（11）：1807-1810.
[8] Moss BJ，Ryter SW，Rosas IO. Pathogenic mechanisms underlying idiopathic pulmonary fibrosis [J]. Annu Rev Pathol，2022，17：515-546.
[9] Heukels P，Moor CC，von der Thusen JH，et al. Inflammation and immunity in IPF pathogenesis and treatment [J]. Respir Med，2019，147：79-91.
[10] Shenderov K，Collins SL，Powell JD，et al. Immune dysregulation as a driver of idiopathic pulmonary fibrosis [J]. JClin Invest，2021，131（2）：e143226.
[11] Jee AS，Sahhar J，Youssef P，et al. Review：serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease-frontiers and horizons [J]. Pharmacol Ther，2019，202：40-52.
[12] 曾珠，王飞，张巍，等.补阳还五汤联合黄芩素对肺纤维化大鼠炎性因子表达的影响研究[J].中国临床药理学杂志，2020，36（1）：29-31.
[13] 邢琳琳，国建飞，阮昕，等.丹参川芎嗪联合泼尼松治疗肺间质纤维化[J].长春中医药大学学报，2019，35（3）：464-467.
[14] 朱德伟，沈云辉.积雪草苷对平阳霉素诱导的大、小鼠肺纤维化的保护作用[J].上海中医药大学学报，2020， 34（6）：41-46.
[15] Judd J，Dulaimi E，Li T，et al. Low level of blood CD4+ T cells is an independent predictor of inferior progression-free survival in diffuse large B-cell lymphoma [J]. Clin Lymphoma Myeloma Leuk，2017，17（2）：83-88.
[16] Yanagihara T，Sato S，Upagupta C，et al. What have we learned from basic science studies on idiopathic pulmonary fibrosis? [J]. Eur Respir Rev，2019，28（153）：190029.
[17] Singh B，Kasam RK，Sontake V，et al. Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine- driven pulmonary fibrosis [J]. Am J Physiol Lung Cell Mol Physiol，2017，313（5）：L796-L806.
[18] Yombo D，Odayar V，Gupta N，et al. The protective effects of IL-31RA deficiency during bleomycin-induced pulmonary fibrosis [J]. Front Immunol，2021，12：645717.
[19] 毛雪丽，张娜，赵鹏飞，等.细胞因子对肺纤维化的影响及机制研究进展[J].临床肺科杂志，2020，25（5）：778- 781.
[20] 杨丽，吕晓东，刘妍彤，等.参龙煎剂干预肺纤维化大鼠血清IFN-γ、IL-4表达水平影响的实验研究[J].中华中医药学刊，2017，35（6）：1427-1430.
[21] Deng Y，Wang Z，Chang C，et al. Th9 cells and IL-9 in autoimmune disorders：pathogenesis and therapeutic potentials [J]. Hum Immunol，2017，78（2）：120-128.
[22] Deng KM，Yang XS，Luo Q，et al. Deleterious role of Th9 cells in pulmonary fibrosis [J]. Cells，2021，10（11）：3209.
[23] Overed-Sayer C，Rapley L，Mustelin T，et al. Are mast cells instrumental for fibrotic diseases? [J]. Front Pharmacol，2014， 4：174.
[24] Noelle RJ，Nowak EC. Cellular sources and immune functions of interleukin-9 [J]. Nat Rev Immunol，2010，10（10）：683-687.
[25] Weng D，Chen XQ，Qiu H，et al. The role of infection in acute exacerbation of idiopathic pulmonary fibrosis [J]. Mediators Inflamm，2019，2019：5160694.
[26] Sugimoto N，Suzukawa M，Nagase H，et al. IL-9 blockade suppresses silica-induced lung inflammation and fibrosis in mice [J]. Am J Respir Cell Mol Biol，2019，60（2）：232-243.
[27] Zhu S，Qian Y. IL-17/IL-17 receptor system in autoimmune disease：mechanisms and therapeutic potential [J]. Clin Sci（Lond），2012，122（11）：487-511.
[28] Desai O，Winkler J，Minasyan M，et al. The role of immune and inflammatory cells in idiopathic pulmonary fibrosis [J]. Front Med（Lausanne），2018，5：43.
[29] Cong LH，Li T，Wang H，et al. IL-17A-producing T cells exacerbate fine particulate matter-induced lung inflammation and fibrosis by inhibiting PI3K/Akt/mTOR-mediated autophagy [J]. J Cell Mol Med，2020，24（15）：8532-8544.
[30] Wang F，Xia H，Yao S. Regulatory T cells are a double- edged sword in pulmonary fibrosis [J]. Int Immunopharmacol，2020，84：106443.
[31] Zhang JH，Deng JH，Yao XL，et al. CD4+CD25+ Tregs as dep- endent factor in the course of bleomycin-induced pulmonary fibrosis in mice [J]. Exp Cell Res，2020，386（1）：111700.
[32] Wang B，Bai W，Ma H，et al. Regulatory effect of PD1/ PD-Ligand 1（PD-L1） on Treg cells in patients with idiopa- thic pulmonary fibrosis [J]. Med Sci Monit，2021，27：e927577.
[33] Garibaldi BT，D’Alessio FR，Mock JR，et al. Regulatory T cells reduce acute lung injury fibroproliferation by decreasing fibrocyte recruitment [J]. Am J Respir Cell Mol Biol，2013，48（1）：35-43.
[34] Chakraborty K，Chatterjee S，Bhattacharyya A. Impact of Treg on other T cell subsets in progression of fibrosis in experimental lung fibrosis [J]. Tissue Cell，2018，53：87-92.
[35] Seyran M，Melanie S，Philip S，et al. Allies or enemies? The effect of regulatory T cells and related T lymphocytes on the profibrotic environment in bleomycin-injured lung mouse models [J]. Clin Exp Med，2023，23（4）：1075-1088.
[36] Sivori S，Pende D，Quatrini L，et al. NK cells and ILCs in tumor immunotherapy [J]. Mol Aspects Med，2021，80：100870.
[37] Celada LJ，Kropski JA，Herazo-Maya JD，et al. PD-1 up- regulation on CD4+ T cells promotes pulmonary fibrosis through STAT3-mediated IL-17A and TGF-beta1 production [J]. Sci Transl Med，2018，10（460）：eaar8356.
[38] Shimizu K，Iyoda T，Yamasaki S，et al. NK and NKT cell- mediated immune surveillance against hematological malignancies [J]. Cancers（Basel），2020，12（4）：817.
[39] Godfrey DI，Le Nours J，Andrews DM，et al. Unconventional T cell targets for cancer immunotherapy [J]. Immunity，2018，48（3）：453-473.
[40] Zhang M，Zhang S. T cells in fibrosis and fibrotic diseases [J]. Front Immunol，2020，11：1142.
[41] Arora S，Thompson PJ，Wang Y，et al. Invariant natural killer T cells coordinate removal of senescent cells [J]. Med，2021， 2（8）：938-950.